We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Sophiris Bio Receives Positive Feedback from FDA Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design PR Newswire SAN DIEGO and VANCOUVER, British Columbia, Oct. 21, 2019 SAN DIEGO...
Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering PR Newswire SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 SAN DIEGO and VANCOUVER, British Columbia, Aug...
Sophiris Bio Announces $4.0 Million Registered Direct Offering PR Newswire SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019 SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019...
Sophiris Bio Receives Positive Feedback from European Medicines Agency Regarding Phase 3 Localized Prostate Cancer Clinical Trial Design Conference call scheduled for today at 9:30 a.m. EDT PR...
Sophiris Bio Reports First Quarter 2019 Financial Results PR Newswire SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 SAN DIEGO and VANCOUVER, British Columbia, May 9, 2019 /PRNewswire/...
Sophiris Bio to Present at Two Upcoming Investor Conferences PR Newswire SAN DIEGO and VANCOUVER, British Columbia, April 2, 2019 SAN DIEGO and VANCOUVER, British Columbia, April 2, 2019...
Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights PR Newswire SAN DIEGO and VANCOUVER, British Columbia, March 13, 2019 SAN DIEGO and...
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial - Reiterates plans to move to Phase 3 with single administration of topsalysin PR Newswire SAN DIEGO and VANCOUVER...
Sophiris Bio to Present at the Piper Jaffray Healthcare Conference PR Newswire SAN DIEGO and VANCOUVER, British Columbia, Nov. 15, 2018 SAN DIEGO and VANCOUVER, British Columbia, Nov. 15, 2018...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions